ArticleCase reports in ophthalmological medicine2025
Optical Coherence Tomography (OCT) Biomarkers for Nonsurgical Management of Postvitrectomy Secondary Macular Holes With Intravitreal Triamcinolone Acetonide (1 mg/0.1 mL): A Case Report of Two Cases.
Article in Case reports in ophthalmological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report optical coherence tomography (OCT) biomarkers for nonsurgical management of secondary macular holes. Case Series: We report two cases in which postvitrectomy macular holes were managed with preservative-free intravitreal triamcinolone acetonide (1 mg/0.1 mL). All the patients underwent OCT examination before and after injection. Patients 1 and 2 experienced closure of the macular hole. The OCT biomarkers for the patients were (1) an apical diameter of less than 100 microns, (2) the presence of subretinal fluid, (3) the presence of a perifoveal cuff of fluid, and (4) the absence of preretinal traction. Discussion: The incidence of secondary macular holes is reported to range from 0.24% to 1.9% of patients who undergo vitrectomy. Secondary macular holes are also reported postvitrectomy due to inadvertent iatrogenic trauma, cystoid macular edema, etc. The treatment of secondary macular holes essentially involves various modifications of the ILM flap technique. There have been reports on the closure of secondary macular holes with the intravitreal injection of triamcinolone acetonide, intravitreal bevacizumab, aflibercept, NSAID, and difluprednate. The identification of OCT biomarkers prior to vitrectomy can help in targeted use of nonsurgical treatment modalities in the management of secondary macular holes with the intravitreal injection of triamcinolone acetonide (1 mg/0.1 mL). Conclusion: Identification of OCT biomarkers can help in the nonsurgical management of secondary macular holes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.